Literature DB >> 9473168

A significant correlation between melatonin deficiency and endometrial cancer.

W Grin1, W Grünberger.   

Abstract

Endometrial cancer is the most common pelvic genital cancer in women. Its incidence is increasing. Unlike the successful screening method for cervical cancer, there is no such equivalent procedure for the early diagnosis of endometrial cancer. Screening procedures currently being tested are too insensitive and nonspecific while diagnostics are either too complex or invasive. In Austria, a multicenter study was begun to search for parameters appropriate for a screening program. 138 women were selected based on anamnestic, serologic and cytologic risk factors. 68 women were diagnosed with endometrial cancer, 70 patients had abnormal bleeding. There were no significant differences in age and menopausal status. Secondary diseases including diabetes mellitus, hypertonia and adipositas were evenly distributed in both groups. In addition to the routine hormone analyses, we tested the patients' plasma for differences in melatonin levels. We found a significant correlation (p < 0.001) between melatonin plasma levels and the presence of endometrial cancer. The mean plasma melatonin value was 6.1 pg/ml in the cancer-positive group and 33.2 pg/ml in the cancer-negative control group resulting in a 6-fold difference between the two groups. We conclude that decreasing melatonin plasma levels may be an indicator of endometrial cancer and that this may therefore be used as a reliable screening parameter.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9473168     DOI: 10.1159/000009926

Source DB:  PubMed          Journal:  Gynecol Obstet Invest        ISSN: 0378-7346            Impact factor:   2.031


  13 in total

1.  Melatonin in aging and disease -multiple consequences of reduced secretion, options and limits of treatment.

Authors:  Rüdiger Hardeland
Journal:  Aging Dis       Date:  2011-02-10       Impact factor: 6.745

2.  Ramelteon, a selective MT1/MT2 receptor agonist, suppresses the proliferation and invasiveness of endometrial cancer cells.

Authors:  Kiyono Osanai; Yoichi Kobayashi; Masahiro Otsu; Tomoko Izawa; Keiji Sakai; Mitsutoshi Iwashita
Journal:  Hum Cell       Date:  2017-04-05       Impact factor: 4.174

Review 3.  Circulating melatonin and the risk of breast and endometrial cancer in women.

Authors:  Akila N Viswanathan; Eva S Schernhammer
Journal:  Cancer Lett       Date:  2008-12-12       Impact factor: 8.679

4.  Sleep, Melatonin, and the Menopausal Transition: What Are the Links?

Authors:  Shazia Jehan; Giardin Jean-Louis; Ferdinand Zizi; Evan Auguste; Seitikurippu R Pandi-Perumal; Ravi Gupta; Hrayr Attarian; Samy I McFarlane; Rüdiger Hardeland; Amnon Brzezinski
Journal:  Sleep Sci       Date:  2017 Jan-Mar

5.  Melatonin enhances DNA repair capacity possibly by affecting genes involved in DNA damage responsive pathways.

Authors:  Ran Liu; Alan Fu; Aaron E Hoffman; Tongzhang Zheng; Yong Zhu
Journal:  BMC Cell Biol       Date:  2013-01-07       Impact factor: 4.241

6.  Chronobiology of Melatonin beyond the Feedback to the Suprachiasmatic Nucleus-Consequences to Melatonin Dysfunction.

Authors:  Rüdiger Hardeland
Journal:  Int J Mol Sci       Date:  2013-03-12       Impact factor: 5.923

7.  Night-time exogenous melatonin administration may be a beneficial treatment for sleeping disorders in beta blocker patients.

Authors:  Auda Fares
Journal:  J Cardiovasc Dis Res       Date:  2011-07

Review 8.  Neurobiology, pathophysiology, and treatment of melatonin deficiency and dysfunction.

Authors:  Rüdiger Hardeland
Journal:  ScientificWorldJournal       Date:  2012-05-02

Review 9.  Protecting the melatonin rhythm through circadian healthy light exposure.

Authors:  Maria Angeles Bonmati-Carrion; Raquel Arguelles-Prieto; Maria Jose Martinez-Madrid; Russel Reiter; Ruediger Hardeland; Maria Angeles Rol; Juan Antonio Madrid
Journal:  Int J Mol Sci       Date:  2014-12-17       Impact factor: 5.923

10.  Combination of Dendrobium Mixture and Metformin Curbs the Development and Progression of Diabetic Cardiomyopathy by Targeting the lncRNA NEAT1.

Authors:  Wenmin Qin; Xing Zhao; Jie Tai; Guoyun Qin; Shanshan Yu
Journal:  Clinics (Sao Paulo)       Date:  2021-07-05       Impact factor: 2.365

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.